Tenofovir gel

DRUG6 trials

Sponsors

Centre for the AIDS Programme of Research in South Africa, CONRAD, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVHIV InfectionsHIV PreventionHealthy

Early Phase 1

Comparison of Tenofovir Vaginal Gel and Film Formulations

CompletedNCT02280109

CONRADHealthy, HIV

Start: 2014-11-30Updated: 2016-01-28

Phase 1

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

CompletedNCT00561496

CONRADHIV Infections

Start: 2007-03-31End: 2008-04-30Updated: 2008-05-28

Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

CompletedNCT00594373

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2010-04-30Updated: 2021-11-01

Phase 2

Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV

CompletedNCT00441298

Centre for the AIDS Programme of Research in South AfricaHIV Infections

Start: 2007-05-31End: 2010-03-31Updated: 2016-02-01

Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women

CompletedNCT00592124

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2008-06-30End: 2010-07-31Updated: 2021-10-19

Phase 3

Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection

CompletedNCT01386294

CONRADHIV Prevention

Start: 2011-10-31End: 2014-08-31Updated: 2015-04-17

Related Papers

Non-<i>Lactobacillus</i>-Dominant and Polymicrobial Vaginal Microbiomes Are More Common in Younger South African Women and Predictive of Increased Risk of Human Immunodeficiency Virus Acquisition

Clinical Infectious Diseases2022-12-1219 citations

A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir Gel

UNC Libraries2020-11-07

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.

2018-10-2469 citations

Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection

New England Journal of Medicine2015-08-0591 citations

Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.

2013-03-058 citations

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.

2013-01-30165 citations

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.

2011-10-1987 citations

A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

2011-01-2573 citations